2 weeks Ago By ABMN Staff
Brandes Investment Partners LP increased its position in Elanco Animal Health Incorporated ( NYSE:ELAN – Free Report ) by 1.3% in the second quarter, HoldingsChannel reports. The firm owned 2,945,967 shares of the company’s stock after acquiring an additional 36,944 shares during the period.
Brandes Investment Partners LP’s holdings in Elanco Animal Health were worth $42,445,000 at the end of the most recent quarter. Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ELAN. Quarry LP purchased a new stake in shares of Elanco Animal Health in the second quarter valued at $40,000.
Creative Planning raised its position in Elanco Animal Health by 7.9% during the second quarter. Creative Planning now owns 52,177 shares of the company’s stock valued at $753,000 after buying an additional 3,801 shares during the period.
Algert Global LLC lifted its stake in Elanco Animal Health by 22.6% in the 2nd quarter. Algert Global LLC now owns 262,298 shares of the company’s stock worth $3,785,000 after acquiring an additional 48,358 shares in the last quarter.
Lighthouse Investment Partners LLC acquired a new stake in Elanco Animal Health during the 2nd quarter worth about $2,561,000. Finally, The Manufacturers Life Insurance Company grew its stake in Elanco Animal Health by 11.3% during the 2nd quarter.
The Manufacturers Life Insurance Company now owns 5,990,546 shares of the company’s stock valued at $86,444,000 after acquiring an additional 609,194 shares in the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.
Elanco Animal Health Stock Performance ELAN opened at $14.32 on Monday. The company has a debt-to-equity ratio of 0.
92, a quick ratio of 1.75 and a current ratio of 2.93.
The company has a market cap of $7.08 billion, a PE ratio of -5.40, a price-to-earnings-growth ratio of 1.
33 and a beta of 1.40. The stock has a 50-day moving average of $14.
05 and a 200-day moving average of $15.07. Elanco Animal Health Incorporated has a 52-week low of $8.
52 and a 52-week high of $18.80. Insider Buying and Selling In other news, CEO Jeffrey N.
Simmons purchased 100,000 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was bought at an average cost of $13.01 per share, for a total transaction of $1,301,000.
00. Following the completion of the acquisition, the chief executive officer now directly owns 145,000 shares of the company’s stock, valued at $1,886,450. The transaction was disclosed in a filing with the SEC, which is available through the SEC website .
In related news, Director Michael J. Harrington bought 3,500 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The shares were acquired at an average price of $14.
85 per share, with a total value of $51,975.00. Following the completion of the transaction, the director now owns 81,094 shares of the company’s stock, valued at approximately $1,204,245.
90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link . Also, CEO Jeffrey N.
Simmons purchased 100,000 shares of the firm’s stock in a transaction on Monday, August 12th. The stock was bought at an average price of $13.01 per share, for a total transaction of $1,301,000.
00. Following the completion of the transaction, the chief executive officer now directly owns 145,000 shares in the company, valued at $1,886,450. The disclosure for this purchase can be found here .
Insiders own 0.57% of the company’s stock. Analyst Upgrades and Downgrades A number of analysts have recently issued reports on ELAN shares.
Piper Sandler reduced their price target on shares of Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating for the company in a research report on Monday, July 1st.
Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 target price on shares of Elanco Animal Health in a research report on Thursday, September 19th. Barclays boosted their price target on shares of Elanco Animal Health from $21.
00 to $22.00 and gave the company an “overweight” rating in a report on Monday, September 23rd. Finally, Morgan Stanley downgraded shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $17.
00 to $15.00 in a research note on Thursday, September 19th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock.
Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $17.43. Read Our Latest Report on ELAN Elanco Animal Health Profile ( Free Report ) Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals.
It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. Further Reading Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated ( NYSE:ELAN – Free Report ).
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter ..
